Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma

Advanced HCC Clinical Trial

Official title:
Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide

Status Completed

Clinical Trial Summary

It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced HCC

Clinical Trial Details

NCT number	NCT00396682
Study type	Interventional
Source	Hannover Medical School
Contact
Status	Completed
Phase	Phase 3
Start date	February 2007
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04601610` - KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma	Phase 1/Phase 2
Not yet recruiting	`NCT05831969` - Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC	Phase 2
Not yet recruiting	`NCT05906524` - KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors	Phase 1/Phase 2